S100B and cancer: However, overexpression of S100B has been reported to promote CRC progression and can be used as an independent predictor of postoperative early relapse.22 Patients with high S100B expression also had a poorer clinical outcome.22 On the contrary, GBP2 is rarely reported among cancers and only Wang et al found that high GBP2 expression increased the sensitivity to paclitaxel in paclitaxel-resistant CRC.12 Therefore, GBP2 was selected for further study.